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Introduction
The production of recombinant gonadotrophins represents a major advance in assisted reproduction. Recombinant follicle stimulating hormone (FSH) has already been successfully used in in-vitro fertilization QVF) programmes (Out et al, 1995; Recombinant Human FSH Study Group, 1995) and the newly available recombinant human luteinizing hormone (rhLH) (LHadi®, Serono) is currently being evaluated clinically (Hull et al, 1994; Baird, 1996) . Preliminary studies in the treatment of hypogonadotrophic hypogonadal women indicate that it promotes normal FSH-induced oestradiol and follicular development (Hull et al, 1994; Baird, 1996) . The use of this preparation may also help define more closely the role of LH in assisted reproduction programmes, particularly as there is evidence to suggest that too much LH may be associated with poor therapeutic outcome (Regan et al, 1990; Chappel and Howies, 1991; Hillier, 1994) and that LH of a different quality is present in patients with polycystic ovarian syndrome (Ding and Huhtaniemi, 1991) . Furthermore, although rhFSH treatment alone during the preovulatory period has been demonstrated to be adequate to promote multiple follicular growth in © European Society for Human Reproduction and Embryology Macaque monkeys (Zelinski-Wooten et al, 1995) , concomitant treatment with rhLH improves embryo viability (Weston et al., 1996) . A further potential use of rhLH will be in its replacement of human chorionic gonadotrophin (HCG) as the ovulatory trigger, as has been demonstrated in nonhuman primates (Chandrasekher et al., 1994) . This may help prevent ovarian hyperstimulation syndrome (Emperaire and Ruffle, 1991) , possibly as a result of the very different half-lives of natural and recombinant LH (measured in hours; Porchet et al, 1995) compared with HCG (measured in days).
The heterogeneity of endogenous human LH extracted from the pituitary (Wide, 1985; Snyder et al, 1987) , serum (Haavisto et al, 1990; Ding and Huhtaniemi, 1991; Wide and Bakos, 1993; Mitchell et al, 1994) and urine (Harlin et al, 1986; Rodgers et al, 1992) is largely dependent on the carbohydrate moities of the hormone which result from post-translational additions and modifications. In particular, charge heterogeneity is derived largely from sulphate and sialic acid residues which terminate the three oligosaccharide chains associated with human LH (Green and Baenziger, 1988) and is dependent on the endocrine status of the donor. For example, it is altered by the endogenous (Haavisto et al., 1990; Mitchell et al, 1994) and exogenous (Matikainen et al., 1994; Wide and Naessen, 1994) steroid milieu as well as gonadotrophin-releasing hormone (GnRH) (Wide et al, 1996) and it is known that the glycoforms of LH and FSH alter in charge during the menstrual cycle, becoming more basic (Padmanabhan et al, 1988; Wide and Bakos, 1993; Zambrano et al, 1995) in the latter stages of follicular maturation. Moreover the complexity of the internal carbohydrate structures in circulating LH varies considerably (Papandreou et al, 1993) . Although the physiological significance of these different forms remains unclear it is known that they relate to metabolic clearance rates with the more sialylated forms of the hormone having longer halflives. However, there is also increasing evidence that the glycoforms of LH, FSH and thyroid-stimulating hormone (TSH) may encode for altered biological potency or even for different functions (Pickles et al, 1992; Mitchell et al, 1994; Lambert et al, 1995; Robertson and Mitchell, 1995) and it may be that this represents a further level of control of the in-vivo biological activity of the hormones. In view of this we have now performed a partial characterization of a pre-clinical batch of Serono rhLH in terms of its in-vitro bio-and immunological potency, the extent of internal carbohydrate branching and degree of overall charge.
Materials and methods

Hormones
Recombinant human LH preparations were obtained from Serono Pharmaceuticals Ltd (Welwyn Garden City, UK, a gift from Dr Hilary Hurst) and Crystal Chem Ltd (Chicago, IL 60660, USA). These preparations were derived from Chinese hamster ovary cells and Mouse L Cell from connective tissue respectively. The stated potency of Serono rhLH (Lot no. C26) was 18187 IU/mg (assessed using an in-vivo bioassay as described by Van Hell et al, 1964) and for Crystal Chem rhLH (Lot no. L002) the stated immunological potency was 20 800 IU/mg in terms of the first international reference preparation (IRP) 68/40. The pituitary-derived LH (pLH) IRP 80/552 (stated biological potency 35 IU/ampoule, 5.8 ug LH/ ampoule) was also studied (Stoning and Gaines Das, 1993) . Each preparation was diluted in Dulbecco's modified Eagle's medium (DMEM; Hyclone, Cramlington, UK) containing 1% bovine serum albumin (BSA fraction V protease-free; Flow-ICN, Thame, UK) to yield a stock containing 10 000 IU/1 as calculated from the stated potency.
Hormone assays
All stock solutions of LH and LH samples obtained following fracuonation were assayed by in-vitro bioassay (Robertson and Bidey 1990) and an in-house two-site polyclonal/monoclonal immunoradiometric assay for LH calibrated against IRP 80/552. Biopotency and immunoreactivity in the unfractionated samples were determined on at least three occasions by producing five dilutions of the 10 000 IU/1 stocks to yield concentrations ranging between 0.2-1.2 IU/1 in the LH bioassay and 0.4-25 IU/1 in the immunoradiometric assay. At least two of the dilutions were parallel to and measurable from the standard curve and were used to calculate the bioactive and immunoreactive content of the preparations. For these assays the standards and test samples were 800 made up in DMEM-BSA. Fractions obtained from chromatofocusing and affinity chromatography procedures were treated as described below, prior to assay for LH activity.
LH immunoradiometric assay
As the different LH charge and carbohydrate structural variants may have different antibody affinities and specificities the immunoradiometric assay we employed for this study used a monoclonal/ polyclonal antibody configuration in an attempt to pick up all the glycoforms present in the preparations. This assay has been previously described by Mitchell et al. (1994) 1:35 dilution in distilled water, adjusted to pH 7.4 with NaOH) containing 0.1% BSA or in the lectin affinity chromatography fractions, 0.05 M phosphate buffer pH 7.4 containing 0.1% BSA for LH determination, so that the standard and fraction matrices were matched. The limit of detection of the assay was 0.2 IU/1 in either buffer as defined by the concentration of LH which gave a statistically significant increase in bound counts over the control (by paired Mest, n = 6 assays). The intra-and inter-assay precision was <8% and <14% at all doses over the standard range. The LH immunoradiometric assay specificity is as determined by National External Quality Assessment Scheme (NEQAS) data. The cross-reactivity with HCG, TSH and FSH was 0.4, 4.3 and <0.1% respectively. As the antibodies are directed to epitopes on different subunits, it is unlikely there is a significant cross-reactivity with free subunits; the monoclonal antibody has a cross-reactivity of <0.01% with a-HCG. Interference by the elution sugars associated with lectin chromatography was investigated on three separate occasions by assaying LH standards (0 and 7 IU/1, 80/552) in the presence of either 10 mM a-D-methylglucopyranoside (a-MG) or 300 mM a-D-methylmannopyranoside (a-MM) diluted in 0.05 M phosphate buffer, pH 7.4 containing 0.1% BSA (identical to the matrix of the column eluents) either undiluted or under a range of dilutions. In the immunoradiometric assay, neither sugar interfered at the maximum concentrations in the chromatography procedure.
LH bioassay
In-vitro LH bioactivity of the unfractionated and fractionated samples was measured using a bioassay based on the dispersed mouse Leydig cell assay described by Van Damme et al. (1974) and modified by us (Robertson and Bidey, 1990) . Samples were diluted in DMEM containing 20 mM HEPES and assayed at a minimum of two dilutions ranging between 1:8-1:256 (dependent on the estimated bioactivity) to assess parallelism. Fractions obtained had to be diluted by >1:8 from both chromatofocusing and lectin chromatography, to avoid interference in the assay. Duplicate samples from all bioassays were removed at the end of the incubation period for determination of testosterone production by a standard in-house radioimmunoassay. The intra-assay precision quoted below reflects the precision of the bioassay system (bioassay and testosterone assay) as a whole. The inter-assay coefficient of variation, based on three quality control samples at 5 IU/1, 16 IU/ 1 and 45 IU/I tested in consecutive assays was <12%. The mean intra-assay coefficient of variation, based on the samples used in this study, was <10%.
Chromatofocusing Preparation of buffers
Distilled deionized water (DDW) filtered through a 0.2 um bottle filter was used throughout for all buffers and solutions. The start buffer for chromatofocussing was bis (2-hydroxyethyl) imino-tris (hydroxymethyl) methane (Ws-Tris, 7.14 mM, pH 7.1-7.2, Sigma Chemical Company, Poole, Dorset). The elution buffer was Polybuffer 74 used at a 1:35 dilution (pH 3.8-4.0). Both buffers were adjusted to their respective pH by titration with saturated iminodiacetic acid (Sigma) and were degassed overnight before use.
Sample preparation
Dilutions of the samples were prepared in Ws-Tris containing 0.1% BSA and passed down a PD-10 column (Pharmacia) to remove any DMEM. Recovery from the PD-10 was 90-110% in all cases. The eluent volume (3.5 ml) was diluted to 10 ml and then degassed for at least 2 h before use.
Procedure
Chiomatofocusing separates proteins on the basis of their isoelectric point over a pre-defined pH range and was performed on a mono-P column (4 ml) in conjunction with a fast performance liquid chromatography (FPLC) system (Pharmacia). The column was washed with 2 M NaCl (0.5 ml) to exchange the storage counter ion prior to an equilibration with Ws-Tris (3O-5Oml, 0.5 ml/min flow rate) until the column pH was equal to that of the start buffer. After loading of the degassed sample (8.5 ml, containing 1 IU LH as assigned on each ampoule) onto the column, elution buffer was pumped through (0.5 ml/minute flow rate) to generate the pH gradient. Fractions (0.95 ml) were collected into tubes containing BSA 2% (50 [i\) in DDW such that the final concentration of BSA was 0.1%. Sampling was continued until the pH of the eluted fractions had fallen to 4.00. All fractions were finally adjusted to pH 7.4 with <50 u.1 of dilute NaOH solution so that the matrix of all fractions was uniform; this minimized interference with the immunoradiometric assay due to polybuffer. The column was then washed with 2 M NaCl (0.5 ml), and proteins with a pi <4.00 were eluted with 10 ml WsTris (salt peak). There was no evidence of interference in the estimation of LH activity in the salt peak and parallelism of diluted salt peak samples (1:2, 1:4 and 1:8) with the standard curve was found on all occasions. All fractions were frozen and stored at -40°C until estimations of LH immuno-and bioactivity could be performed. Recoveries of immunoreactive (I-LH) and bioactive (B-LH) LH from the chromatofocusing columns (expressed as a percentage of that applied) were 86-123%. The coefficient of variation of the procedure, based on three samples from the same pool run in separate experiments, was 20% (Grabinski et al., 1992) .
Concanavalin A lectin affinity chromatography
This procedure was based on the method described by Papandreou et al. (1993) and used CONA-5 concanavalin A (Con-A) preprepared columns (ConA-5; 2.5 ml, Sigma) in accordance with the manufacturer's instructions. Con-A permits the separation of pituitary glycoprotein hormones into three bands of material whose constituent glycoforms either do not bind (complex forms, triantennary, tetraantennary and bisecting), are weakly bound (biantennary and truncated hybrid) or are strongly bound (high mannose and hybrid) to the immobilized lectin (Snyder et al., 1989; Papandreou et al, 1993) . Columns were regenerated by first passing five column volumes (12.5 ml) of 0.1 M sodium borate buffer (pH 8.5) followed by 0.1 M sodium acetate/sodium chloride solution (pH 4.5). Prior to use, the columns were prewashed in five column volumes of a solution containing 1 M sodium chloride, 5 mM calcium chloride dihydrate, 5 mM magnesium chloride and 5 mM manganese (II) chloride in distilled water before the addition of five column volumes of 0.05 M phosphate buffer, pH 7.4 containing 0.1% BSA. Sample (100 ul of the 10 000 IU/1 stock solutions) was applied to the top of the column and the void volumn discarded. Material which was non-binding to the column was collected by passing 5 ml of buffer 1 (0.05 M phosphate buffer pH 7.4 containing 0.1% BSA) down the column in 0.5 ml aliquots. Material that was weakly bound to the column was eluted with 25 ml of buffer 1 containing 10 mM a-MG, again in 0.5 ml aliquots. Any remaining firmly bound material was then eluted with 13 ml of 300 mM a-MM. All fractions were frozen and stored at -20°C until immunoassay and bioassay for LH could be performed. Recoveries of immunoreactive (I-LH) and bioactive (B-LH) LH from the lectin columns ranged between 83-144%. The coeficient of variation of the Con-A procedure was assessed by performing three LH runs with the same stock solution and the precision associated with the proportions of simple and intermediate structures was 1.5 and 6.3% (bioactive material) and 11.8% and 10.2% (immunoreactive material).
Statistical analysis
Comparison of LH B:I ratios was performed by unpaired Student's f-test. Association of variables was analysed by Pearson's correlation coefficient. Statistical significance was defined as P <0.05. All values presented are expressed as mean ± SEM.
Results
Potency
The in-vitro biopotencies (B-LH), immunoreactive (I-LH) potencies and the B:I ratios of the preparations are shown in Table I . Using the stated potencies as the basis of our calculation and preparation of the start solution (see Materials and Methods) the Serono recombinant preparation was more biopotent than the other preparations (18 187 ± 1331 IU/ mg; P <0.05) and had a higher B:I ratio (1.99 ± 0.30; P <0.02) than the pituitary LH.
Chromatofocusing
The B-LH pH distribution over the pH range 7-4 for each preparation is shown in Figure 1 (A-C) . The two recombinant preparations had LH activity throughout the pH range used, in contrast to the pLH material which focused tightly in the range 5.75-4.01. However, the Serono rhLH was more broadly distributed (ranging between 6.5-5.01) than the Crystal Chem rhLH, which had a clear peak of activity at 5.75-5.51 containing 20% of the LH. In contrast, > 50% of the LH in the pituitary 80/552 standard focused between 5.25-4.76, peaking at pH 5.14. The I-LH profiles (data not shown) were similar to those seen for B-LH and this is confirmed when the data are summarized as the percentage of LH appearing in 1 pH unit intervals (Table II) . There were large variations in the proportion of B-LH with a pi < 4 with only 6.9% of the Serono rhLH in this band. The recombinant preparations had 50-60% of B-LH at a pi 5-6 with a median pi of 5.50 (Serono) and 5.52 (Crystal Chem). Pituitary LH 80/552 had almost equal proportions of B-LH in the pH ranges 4-5 and 5-6 (-40% in each); the median pi lay at 4.97 and this preparation was clearly the most acidic (18% < pi 4) while the Serono rhLH was the most basic of the preparations (24.6% > pi 6).
Whilst the proportions of B-and I-LH were similar when the data were pooled into defined 0.25 pi unit intervals, the relationship between the less acidic forms of LH and the B:I ratio in individual fractions varied between a positive correlation (r = 0.674, P < 0.0001) for Crystal Chem rhLH, no relationship for Serono rhLH, and a poor negative correlation for pLH (r = -0.374, P = 0.01).
Lectin affinity chromatography
The B-LH elution profiles obtained following con-A lectin affinity chromatography are shown in Figure 2 . LH resolved into three discrete bands containing complex (fractions 1-10), intermediate (fractions 11-60) and simple (fractions 61-86) carbohydrate structures. The proportion of I-LH and B-LH within each complexity band was calculated as a percentage of the total eluted (Table HI) . Interestingly, none of the preparations studied had >0.8% complex oligosaccharide structures, with the bulk of B-LH in all cases being of simple or intermediate complexity. The three preparations contained 63, 57 and 56% simple forms B-LH for the Serono, Crystal Chem and pituitary material respectively. Overall the I-LH profiles were again similar to that seen for B-LH (data not shown for profiles but summarized in Table III) .
Finally, the relationship between carbohydrate complexity and charge was examined by relating the percentage of simple forms with the proportion of LH of pi < 4 ( Figure  3 ). There was a negative relationship (r = -0.955, P < 0.05) between these two parameters for I-LH particularly when data from the urinary LH standard 70/45 was included in addition to the other preparations. However, this relationship was not seen for bioactive LH; 70/45 could not be included in the analysis in this case as this preparation contains HCG which extensively cross-reacts in the LH bioassay. 
Discussion
To date purified human LH has not been available for clinical use, and menopausal urinary gonadotrophin and HCG (due to its LH-like activity) have been used to treat hormonal abnormalities associated with infertility in men and women. The advent of recombinant LH (Simon et ai, 1988) should diminish the problems associated with maintaining the consistency of the quality and quantity of gonadotrophins in urinary preparations (see Rodgers et ai, 1992 Rodgers et ai, , 1995 . Further, the use of recombinant gonadotrophins should permanently alleviate the problem of the world-wide shortage of these preparations for assisted reproduction which has been a severe difficulty in the last 2 years. These molecules will also provide clinicians with the option of adjusting LH:FSH treatment regimens in a controlled way and will enable more physiological approaches to assisted reproduction programmes to be developed, e.g. by the substitution of HCG with LH as the ovulatory trigger. Finally, recombinant LH and other similar human recombinant molecules are likely to have a major role in the standardization of hormone assay kits used for clinical investigation (Rose and Gaines Das, 1996) . In our study, we have assessed the immunological and in-vitro biopotency of two recombinant human LH preparations and performed a partial characterization of their glycoform composition, and compared these data against the pituitary 80/552 reference preparation.
It should be borne in mind that any study of glycoprotein hormone immunoreactivity and B:I ratios needs to be interpreted with caution. The possibility that different immunoassays selectively measure different glycofonms has been postulated (Chappel, 1990; Stoning, 1992; Robertson and Mitchell, 1995) although this has been disputed (Jeffcoate, 1993) . We used an immunoradiometric assay with a broad spectrum polyclonal capture antibody in order to maximize the chances of binding all the LH glycoproteins that were present. However we did employ a monoclonal antibody as the reporter. A different approach would be to use a radioimmunoassay which is entirely dependent upon polyclonal antibodies (see Lambert et ai, 1995) but such systems are less precise and less specific than the immunoradiometric assay (Chappel, 1990) . So, although the choice of assay system is difficult, of greater importance in such studies is that the same assay is used for all preparations and that all estimates are calibrated against the same standard, IRP 80/552 in our case.
As expected, the in-vitro bio-and immunological potencies of the Serono and Crystal Chem rLH preparations varied considerably from their assigned values. These were originally calculated on the basis of the van Hell in-vivo bioassay and an immunoassay calibrated against the IRP 68/40 standard respectively. However, when the preparations were calibrated against purified LH IRP 80/552 and related on a mass basis (see the Materials and methods section) it was clear that the Serono material had both the highest immunological and the highest in-vitro biological potency. Overall, the bioactive and immunoreactive profiles obtained from chromatofocusing and affinity chromatography were similar for the recombinant preparations. However, the Serono rLH had the greatest proportion of B-LH glycoforms with a pi > 6 (25% compared to 19.% and 0% for Crystal Chem and pLH respectively). The glycoforms were distributed over a larger pH range (4-7) than the pLH in which the greatest proportion of LH was found in the range pH 4.75-5.24 with just 1% immunoreactive material in the range pH > 6 and 17.1% pH < 4. However, the profile observed for the pLH preparation may not necessarily reflect that present in the human pituitary which itself varies between pre-and post-menopausal women (Reader et al, 1983) but is more likely to be a consequence of the purification procedures used in the preparation of the material. Of some concern to us was the report of Papandreou et al. (1993) , who determined the isoelectric focusing point of the same preparation to be 9.2-7.3 by polyacrylamide gel electrophoresis in the presence of ampholines. However, similar discrepancies between the determination of pi by chromatofocusing (5.2-6.8) and iso-electric focusing (6-8.6) techniques have been seen for TSH (Pickles et al., 1992; Medri et al., 1994) and the explanation may lie within the technical basis of the two methods.
It could be argued that a recombinant preparation with a broad range of pi forms is likely to be more suitable for general clinical use in assisted reproduction, since the natural charge variants for plasma LH vary considerably. For example, more than six major peaks (range from fewer than four to nine) have been identified in follicular phase (day 10) plasma samples and it is known that even more basic material predominates at the mid-cycle surge and in patients with polycystic ovary syndrome (Strollo et al., 1981; Ding and Huhtaniemi, 1991; Wide and Bakos, 1993) . Although the proportion of forms of pi > 6 in the Serono rLH (25%) was greater than for the other preparations, it was less than the proportion of basic LH isoforms (31.2-35.4%, pi > 7) reported by Ding and Huhtaniemi (1991) for normal women. However, the limited chromatofocusing data available for normal men show that LH glycoforms are distributed over the pH range 6.69-4.60 (Mitchell et al, 1994) and the more acidic LH species have longer in-vivo activity (UlloaAguirre et al, 1988) , suggesting that this material may represent a useful compromise between the widely variant natural forms.
LH profiles following concanavalin A affinity chromatography were similar when analysed by in-vitro bioassay and immunoassay. The pituitary and recombinant LH preparations 804 had very similar binding patterns indicative of similar carbohydrate side chain complexities; overall we found a large, clearly-defined peak of simple high mannose species and a broad band of intermediate forms with <2% of the total LH appearing in any one fraction. However, it is highly unlikely that this intermediate profile represents a non-specific background as, with the exception of the few fractions which had undetectable LH, the amount of LH measured was at least twice the limit of detection of the assays, both of which have been fully validated for specificity using the matrix employed during the Con A chromatography. Further, we assessed the reproducibility of the recovery of LH in the different bands and when the same sample was run three times, the precision (% coefficient of variation) associated with the proportions of intermediate carbohydrate species was 6.3 (B-LH) and 10.2 (L-LH), i.e. similar to the interassay variation associated with the immunoradiometric or bioassay. If the chromatography procedure had a variable background, then we would have seen a much larger overall error and these findings provide further evidence that the detected intermediate sugar structures are genuine.
Our findings on the distribution pattern of the complexity of the carbohydrate chains are in agreement with those of Papandreou et al. (1993) for IRP 80/552. However, this is in contrast to the limited data available for serum from normal males and females during the follicular phase, in which >30% complex forms were detected (Papandreou et al, 1993) . We have similar data for recombinant FSH (Puregon) in which there were 6% complex forms in comparison with >45 for plasma FSH in the follicular phase of the menstrual cycle and in post-menopausal women (Papandreou et al, 1993; Creus et al, 1996; Harris et al, 1996) . This difference presumably reflects the limited ability of Chinese hamster ovary cells to introduce complex branched carbohydrate structures onto the protein core in comparison with the natural synthetic cells, the gonadotrophs. However, this does not appear to compromise either the invitro or the in-vivo bioactivity as both of these preparations have proven clinical efficacy. However, the higher proportion of simple (high mannose) and intermediate glycoforms (with few neuraminic acid residues) suggests that the Serono rLH preparation should have a shorter in-vivo half-life than natural LH. This turns out not to be the case as Porchet et al. (1995) have shown that the initial and terminal halflives of rLH and pituitary LH are 0.8/11 and 0.6/10 h respectively. However, as mentioned earlier, this relatively short circulatory half-life may prove useful in assisted reproduction in aiding the development of more 'physiological' treatment regimens. Moreover, as the addition of the carbohydrate chains to the protein sub-unit core of the hormone is a post-translational modification, the extent of the internal complexity and of the final overall charge will depend on the enzymatic capability of the cells and as such may vary both between different mammalian cell types and in different cell culture conditions even if the same cDNA was used to transfect the cell line. This will clearly allow for the development of specific forms of LH which could be 'designed' for a particular therapeutic purpose.
In conclusion recombinant LH preparations have high invitro bioactivity, contain a broad spectrum of charged variants but contain a lower proportion of glycoforms with complex carbohydrate structures relative to previously reported data from normal physiology.
